Table 2 Adjusted and Unadjusted Means of OGTT at one-year follow-up for cases and controls

From: Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

  Group Unadjusted Means Adjusted mean Adjusted mean difference with 95% CI
Baseline Follow-up
BMI (Kg/m2) Cases 21.0 (1.79) 21.6 (1.65) 21.5 (0.387) 0.5 [− 0.6–1.6]
  Controls 20.7 (2.94) 20.9 (2.64) 21 (0.387)  
FEV1 (% predicted) Cases 85.5 (24.3) 85.2 (23.0) 85.6 (3.8) 4.5 [− 7.8–16.8]
  Controls 81.9 (20.1) 81.7 (26.9) 81.1 (4.5)  
Basal glucose (mg/dL) Cases 87.2 (16.2) 89 (10.4) 86 (2.7) 8.7 [0.7–16.7]
  Controls 77.2 (12.8) 74.2 (14.6) 77.2 (2.7)  
120 min glucose (mg/dL) Cases 123 (49) 131 (72) 136 (14)  − 6 [− 48–36]
  Controls 135 (59) 148 (68) 142 (14)  
Glucose AUC Cases 7.54 (1.81) 7.72 (2.61) 7.79 (0.44)  − 0.03 [− 1.35–1.29]
  Controls 7.67 (1.83) 7.89 (2.05) 7.82 (0.46)  
β-cell glucose sensitivity (pmol × min−1 × m−2 × mM−1) Cases 69.2 (51.3) 56.2 (33.0) 52.7 (6.1)  − 6.1 [− 24.7–12.4]
  Controls 55.6 (35.2) 55 (25.1) 58.9 (6.4)  
30 min C-peptide (ng/mL) Cases 4.3 (2.2) 3.7 (1.4) 3.4 (0.3) 0.0 [− 0.9–0.9]
  Controls 3.2 (1.5) 3.1 (1.3) 3.4 (0.3)  
30 min insulin (µU/mL) Cases 40 (30) 25 (16) 23 (4) 4 [− 8–16]
  Controls 20 (16) 17 (10) 19 (3)  
OGTT insulin clearance (L × min−1 × m−2) Cases 1.27 (0.35) 1.75 (0.69) 2.13 (0.55)  − 0.14 [− 1.88–1.60]
  Controls 1.74 (0.54) 2.68 (2.73) 2.27 (0.57)  
2 h OGIS (ml × min−1 × m−2) Cases 439 (56) 458 (49) 460 (37)  − 67 [− 170–36]
  Controls 527 (74) 542 (87) 527 (24)  
  1. Standard deviations for unadjusted means and standard errors for adjusted mean